SPIKEVAX (mRNA encoding SARS-CoV-2 spike protein, 5’(m7G-5’-ppp-5’-Gm) cap, 100-nucleotide 3' poly(A) tail) [KP.2 strain]

Share:

Product description

Brand name
SPIKEVAX
Company name
Moderna Biopharma Canada Corporation
Ingredient
mRNA encoding SARS-CoV-2 spike protein, 5’(m7G-5’-ppp-5’-Gm) cap, 100-nucleotide 3' poly(A) tail
Date of approval

Resources

Click on a resource to visit a page with more information. You may be taken away from this page to a different Government of Canada website.

For consumers For health care professionals For researchers All resources
Updated Date Resources for Resources Description Date
Health Care Professionals, Researchers Product Monograph

The Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use.

The Product Monograph includes three sections:

  • Part I: Health Professional Information;
  • Part II: Scientific Information; and
  • Patient Medication Information
Health Care Professionals, Researchers Post-Authorization Activity Table (PAAT)

The Post Authorization Activity Table includes brief summaries of the activities that occur after the approval of the product. It is updated on a monthly basis.
Health Care Professionals, Researchers Authorization Terms & Conditions

For COVID-19 authorizations, Health Canada can impose terms and conditions on the authorization. This allows Health Canada to continue to gather information on the safety, effectiveness and/or quality of the product. The status of the terms and conditions will be updated on a regular basis.

Note: This product (SPIKEVAX) includes an update to the antigen composition (variant Omicron KP.2) and replaces SPIKEVAX XBB.1.5 (andusomeran).

Page feedback
Did you find what you were looking for?
Date modified: